Granules India Limited (GRANULES) — Financial Results(2 announcements)

Investor Takeaways

Overall Tone: Neutral

Key Financial Highlights

What Changed

Granules India reported strong profitability expansion in Q1FY27, with net profit rising 60% YoY to ₹1,800 crores and EBITDA growing 37% to ₹3,389 crores. The company also reduced its net debt to ₹1,012 crores, supporting a healthier balance sheet. ROCE improved to 18.0%, reflecting better capital efficiency. Revenue growth of 22% YoY was robust, though the filing notes sequential softness in EBITDA, indicating potential margin pressure or operational volatility. The forward-looking strategy emphasizes complex product development and global market expansion, positioning the company for long-term growth despite external cost headwinds. However, the lack of quarterly trend data for the current fiscal year limits assessment of recent momentum.

Peer Comparison

Granules trades at a discount to Sun Pharma and Divi's in terms of P/E, but its ROCE of 18.0% is below both peers. The company’s lower valuation may reflect market skepticism about sustainability of profitability gains or growth visibility.

Risks & Concerns

Quarterly Trend

The quarterly trend shows declining profitability metrics in recent quarters, with OPM and profit levels trending downward from Q3FY25 to Q4FY24. However, the current filing reports significantly higher absolute figures for Q1FY27 (₹14,768 Cr revenue, ₹1,800 Cr profit), suggesting a structural shift or potential data inconsistency. Without clarification, the trend cannot be reliably interpreted.

Note: The Quarterly Trend section reflects only the data provided in the context. The large discrepancy between historical quarterly revenues (in the ₹1,000 Cr range) and the current filing’s ₹14,768 Cr revenue indicates either a reporting scale change, consolidation effect, or data anomaly. This requires further clarification for accurate analysis.

Investor Takeaways

Overall Tone: Positive

Key Financial Highlights

What Changed

The financial results reflect a structural improvement in Granules India's operational and financial profile. Revenue growth of 22% YoY to ₹14,768 Cr was led by the Complex Gx segment, which now contributes 50% of FD revenue, enhancing revenue concentration in higher-margin products. Gross margin improved to 65.6% (+74 bps YoY), driven by this shift in product mix. PAT growth outpaced revenue growth at 60% YoY, indicating effective cost management and operational leverage. EBITDA rose 37% YoY to ₹3,389 Cr, reinforcing margin expansion. The company’s balance sheet strengthened materially, with Net debt/EBITDA declining to 0.07x from 0.34x, reducing financial risk. ROCE increased to 18.0% (~196 bps YoY), reflecting improved capital efficiency. R&D investment of ₹880 Mn (6.0% of sales) underscores commitment to innovation and pipeline development. The company also achieved a VAI FDA inspection outcome for its Virginia facility and has 25 ANDAs under approval, positioning it for sustained growth in regulated markets like the US.

Peer Comparison

Granules India trades at a P/E below Sun Pharma and significantly below Divi's and Torrent, despite delivering higher ROCE than Sun Pharma and strong profitability metrics. Its ROCE of 18.0% is competitive within the peer set, and the company demonstrates healthier leverage management compared to peers with higher debt ratios.

Risks & Concerns

Quarterly Trend

The latest quarter’s revenue of ₹14,768 Cr (as reported in Q1 FY27) appears to be an annual figure, as it significantly exceeds the quarterly revenues in the trend (which are in the range of ₹1,100–1,200 Cr). The quarterly trend reflects sequential stability in profitability and margins over the past four quarters, with OPM remaining relatively flat around 21%. The reported Q1 FY27 results represent a full-year annualized performance or a consolidated annual filing, given the scale of revenue and profit figures.

About Granules India Limited (GRANULES)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

View full GRANULES stock details →